(NASDAQ: PRLD) Prelude Therapeutics's forecast annual revenue growth rate of 96.49% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.9%.
Prelude Therapeutics's revenue in 2026 is $22,424,000.On average, 5 Wall Street analysts forecast PRLD's revenue for 2026 to be $5,383,064,277, with the lowest PRLD revenue forecast at $1,717,690,211, and the highest PRLD revenue forecast at $9,242,839,633. On average, 4 Wall Street analysts forecast PRLD's revenue for 2027 to be $4,612,162,612, with the lowest PRLD revenue forecast at $1,041,834,497, and the highest PRLD revenue forecast at $8,379,365,925.
In 2028, PRLD is forecast to generate $16,279,910,940 in revenue, with the lowest revenue forecast at $15,641,483,060 and the highest revenue forecast at $16,758,731,850.